echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > Neurology: In patients with recurrent multiple sclerosis, age has a greater impact on mortality than disease duration

    Neurology: In patients with recurrent multiple sclerosis, age has a greater impact on mortality than disease duration

    • Last Update: 2021-06-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Multiple sclerosis (MS) is a central nervous system of its own immune and demyelinating diseases
    .


    Its mortality rate is higher than that of the general population matched by age and sex


    immunity

    The second framework, which is widely used in cancer research but rarely used in multiple sclerosis, uses an additive model, assuming that the mortality rate is the sum of the expected mortality rate and the excess mortality rate (EDR) caused by the disease
    .


    Describing the dynamics of EDR and the impact of covariates on this dynamic is an important task.


    Using this innovative method, Fabien Rollot and others of the University of Lyon in France described the dynamics of EDR in France according to the duration of the disease or the current age, and studied the influence of the age at the onset of multiple sclerosis on these dynamics.
    Multiple sclerosis phenotypes were studied separately
    .


    The second goal is to study the impact of gender on EDR


    They used data from 18 French multiple sclerosis specialist centers, which included multiple sclerosis patients living in French metropolises who had clinically onset between 1960 and 2014
    .


    The life status was updated on January 1, 2016


    They found that out of 37524 patients (71% were women), 2883 (7.
    7%) deaths were observed and 7.
    8% lost follow-up
    .


    For R-MS patients, there is no excess mortality in the first 10 years after the onset of disease;

    After that, regardless of the age at the time of onset, the excess mortality rate increases with the current age
    .


    Starting from the current age of 70 years, the value of the excess mortality rate tends to be consistent, regardless of the age at the time of onset, which means that the duration of the disease has no more impact


    Regardless of the age at the time of onset, the excess mortality rate increases with the current age



    Original source:

    Effects of Age and Disease Duration on Excess Mortality in Patients With Multiple Sclerosis From a French Nationwide CohortFabien ROLLOT, Mathieu Fauvernier, Zoe Uhry, Sandra Vukusic, Nadine Bossard, Laurent Remontet, Emmanuelle Leray, OFSEP Investigators

    Effects of Age and Disease Duration on Excess Mortality in Patients With Multiple Sclerosis From a French Nationwide CohortFabien ROLLOT, Mathieu Fauvernier, Zoe Uhry, Sandra Vukusic, Nadine Bossard, Laurent Remontet, Emmanuelle Leray, OFSEP Investigators

    Neurology May 2021, 10.


    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.